SPI Premium Insight: HeartBeam Tests Ambulatory DCAR Market’s Pulse with LIVMOR Deal

Earlier this month, cardiac technology company HeartBeam acquired the assets of digital health solutions company LIVMOR, including LIVMOR’s Halo+ Atrial Fibrillation (AF) Detection System. 

HeartBeam’s move to acquire the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring aligns with its goals to improve patient outcomes and reduce healthcare system costs. But in a fast-moving ambulatory diagnostic cardiology space, will the LIVMOR deal be the disruptive ‘game changer’ that some observers believe?